Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice

Cabibbo, Giuseppe; Celsa, Ciro; Rimassa, Lorenza; Torres, Ferran; Rimola, Jordi; Kloeckner, Roman; Bruix, Jordi; Cammà, Calogero; Reig, Maria

doi:10.1016/j.jhep.2024.01.018

Cited by 3 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although network pharmacology and in vitro and in vivo experiments have confirmed the anticancer potential of hawthorn, suggesting that it could be used as adjuvant therapy in cancer treatment, further validation of hawthorn’s efficacy in combating cancer through clinical trial data is required, given the complexity of cancer treatment and the unique nature of TCM. Only through clinical trials can the optimal dose and mode of administration of the drug be determined, as well as comprehensively assessing its side effects and potential risks ( Ness and Royce, 2017 ; Cabibbo et al, 2024 ). Furthermore, clinical trials can provide further clarification on the pharmacological mechanism and systematically verify the anticancer efficacy of hawthorn using scientific methods.…”

Section: Clinical Trialsmentioning

confidence: 99%

Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms

Zhou,

Nan,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Over the past few years, there has been a gradual increase in the incidence of cancer, affecting individuals at younger ages. With its refractory nature and substantial fatality rate, cancer presents a notable peril to human existence and wellbeing. Hawthorn, a medicinal food homology plant belonging to the Crataegus genus in the Rosaceae family, holds great value in various applications. Due to its long history of medicinal use, notable effects, and high safety profile, hawthorn has garnered considerable attention and plays a crucial role in cancer treatment. Through the integration of modern network pharmacology technology and traditional Chinese medicine (TCM), a range of anticancer active ingredients in hawthorn have been predicted, identified, and analyzed. Studies have shown that ingredients such as vitexin, isoorientin, ursolic acid, and maslinic acid, along with hawthorn extracts, can effectively modulate cancer-related signaling pathways and manifest anticancer properties via diverse mechanisms. This review employs network pharmacology to excavate the potential anticancer properties of hawthorn. By systematically integrating literature across databases such as PubMed and CNKI, the review explores the bioactive ingredients with anticancer effects, underlying mechanisms and pathways, the synergistic effects of drug combinations, advancements in novel drug delivery systems, and ongoing clinical trials concerning hawthorn’s anticancer properties. Furthermore, the review highlights the preventive health benefits of hawthorn in cancer prevention, offering valuable insights for clinical cancer treatment and the development of TCM with anticancer properties that can be used for both medicinal and edible purposes.

show abstract

Section: Clinical Trialsmentioning

confidence: 99%

Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms

Zhou,

Nan,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma

Papadakos,

Chatzikalil,

Vakadaris

et al. 2024

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and presents a continuously growing incidence and high mortality rates worldwide. Besides advances in diagnosis and promising results of pre-clinical studies, established curative therapeutic options for HCC are not currently available. Recent progress in understanding the tumor microenvironment (TME) interactions has turned the scientific interest to immunotherapy, revolutionizing the treatment of patients with advanced HCC. However, the limited number of HCC patients who benefit from current immunotherapeutic options creates the need to explore novel targets associated with improved patient response rates and potentially establish them as a part of novel combinatorial treatment options. Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and promotes CD8+ and CD4+ effector T-cell function with simultaneous inhibition of Tregs function, when activated by its ligand, GITRL. GITR is currently considered a potential immunotherapy target in various kinds of neoplasms, especially with the concomitant use of programmed cell-death protein-1 (PD-1) blockade. Regarding liver disease, a high GITR expression in liver progenitor cells has been observed, associated with impaired hepatocyte differentiation, and decreased progenitor cell-mediated liver regeneration. Considering real-world data proving its anti-tumor effect and recently published evidence in pre-clinical models proving its involvement in pre-cancerous liver disease, the idea of its inclusion in HCC therapeutic options theoretically arises. In this review, we aim to summarize the current evidence supporting targeting GITR/GITRL signaling as a potential treatment strategy for advanced HCC.

show abstract

Potential value and advances in research on bone mineral density (BMD) measurement in the auxiliary clinical assessment of hepatocellular carcinoma

Zhang,

Chen,

Song

et al. 2024

BST

View full text Add to dashboard Cite

Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice

Cited by 3 publications

References 81 publications

Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms

Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms

Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma

Potential value and advances in research on bone mineral density (BMD) measurement in the auxiliary clinical assessment of hepatocellular carcinoma

Contact Info

Product

Resources

About